CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Diadexus, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Diadexus, Inc.
349 Oyster Point Blvd
Phone: (650) 246-6400p:650 246-6400 South San Francisco, CA  94080-1947  United States Fax: (650) 246-6499f:650 246-6499
This company is no longer actively traded on any major stock exchange.
Business Summary
Diadexus, Inc., also known as VaxGen, Inc, is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of their patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201612/31/2015YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Lori F.Rafield 60 4/20/2015 5/19/2008
Chief Financial Officer Leone D.Patterson 57 3/2/2015 3/2/2015
Executive Vice President, Chief Technology Officer EmiZychlinsky 59 1/1/2011 1/1/2011
7 additional Officers and Directors records available in full report.

Business Names
Business Name
DDXS
DDXSQ
diaDexus, LLC
VaxGen, Inc.
VaxGen-Celltrion, Inc.

General Information
Number of Employees: 38 (As of 12/31/2015)
Outstanding Shares: 4,100,060 (As of 4/28/2016)
Shareholders: 72
Stock Exchange: OTC
Federal Tax Id: 943236309
Fax Number: (650) 246-6499
Email Address: webmaster@vaxgen.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023